SKINOVATION PHARMACEUTICAL INCORPORATED: 10-Q filed 2013-11-13
What SKINOVATION PHARMACEUTICAL INCORPORATED reported in its quarterly report filed 2013-11-13 (fiscal Q3 2013): 20 published measures, 60 facts as tagged in accession 0001554795-13-000684.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-11-13
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001554795-13-000684 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SKINOVATION PHARMACEUTICAL INCORPORATED filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,941 | USD | |
| At 2012-12-31 | 115 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 143,255 | USD | |
| At 2012-12-31 | 110,968 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -139,314 | USD | |
| At 2012-12-31 | -110,853 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,941 | USD | |
| At 2012-12-31 | 115 | USD | |
| At 2012-09-30 | 1,120 | USD | |
| At 2011-12-31 | 348 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -8,061 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -28,461 | USD | 273 |
| 1988-01-15 to 2013-09-30 | -165,170 | USD | 9391 |
| 2012-07-01 to 2012-09-30 | 32,967 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 8,525 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -10,174 | USD | 273 |
| 1988-01-15 to 2013-09-30 | -41,140 | USD | 9391 |
| 2012-01-01 to 2012-09-30 | 25,627 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1988-01-15 to 2013-09-30 | 5,264 | USD | 9391 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1988-01-15 to 2013-09-30 | 40,977 | USD | 9391 |
| 2012-07-01 to 2012-09-30 | 40,977 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 40,977 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 14,000 | USD | 273 |
| 1988-01-15 to 2013-09-30 | 50,345 | USD | 9391 |
| 2012-01-01 to 2012-09-30 | -24,855 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1988-01-15 to 2013-09-30 | -5,264 | USD | 9391 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 708,000 | shares | 92 |
| 2013-01-01 to 2013-09-30 | 708,000 | shares | 273 |
| 2012-07-01 to 2012-09-30 | 708,000 | shares | 92 |
| 2012-01-01 to 2012-09-30 | 708,000 | shares | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -6,200 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -23,230 | USD | 273 |
| 1988-01-15 to 2013-09-30 | -135,442 | USD | 9391 |
| 2012-07-01 to 2012-09-30 | 34,635 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 14,024 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,941 | USD | |
| At 2012-12-31 | 115 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 1,861 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 5,231 | USD | 273 |
| 1988-01-15 to 2013-09-30 | 18,728 | USD | 9391 |
| 2012-07-01 to 2012-09-30 | 1,668 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 5,499 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 143,255 | USD | |
| At 2012-12-31 | 110,968 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 36,000 | USD | |
| At 2012-12-31 | 22,944 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 6,200 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 23,230 | USD | 273 |
| 1988-01-15 to 2013-09-30 | 176,419 | USD | 9391 |
| 2012-07-01 to 2012-09-30 | 6,342 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 26,953 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 708,000 | shares | |
| At 2012-12-31 | 708,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 25,148 | USD | |
| At 2012-12-31 | 25,148 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 6,200 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 23,230 | USD | 273 |
| 1988-01-15 to 2013-09-30 | 176,419 | USD | 9391 |
| 2012-07-01 to 2012-09-30 | 6,342 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 26,953 | USD | 274 |
Inspect the source
- Entity
- SKINOVATION PHARMACEUTICAL INCORPORATED / CIK 0001118072
- Captured
- 2026-09-21T17:18:22.262Z
- SEC response SHA-256
2a8f12373902fb089789064a50866081690b54ca91a66a8d71a686a973e9e781
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001118072.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))